Clovis (NASDAQ:CLVS) was forced to admit an unpleasant defeat after data emerged showing no significant difference in survival rates for advanced pancreatic cancer patients treated with the company's drug candidate CO-101 versus the current chemotherapy treatment, gemcitabine. The news caused the stock to drop by nearly 40% on Monday. In this video, Motley Fool health care analyst Brenton Flynn tells us how the company plans to move forward in the face of these big losses, and why this has been a difficult space for other companies as well.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
